The brain tumor drugs market is estimated to record a 9.2% CAGR from 2023 to 2033. The market is likely to reach US$ 2.65 billion in 2023 and is expected to be worth US$ 6.30 billion in 2033.
| Report Attribute | Details |
|---|---|
| Brain Tumor Drugs Market Value (2023) | US$ 2.65 billion |
| Brain Tumor Drugs Market Anticipated Value (2033) | US$ 6.30 billion |
| Brain Tumor Drugs Market Growth Rate (2023 to 2033) | 9.2% CAGR |
Surging Neurological Condition to Increase the Demand
Rising awareness of neurological illnesses in children and adults is boosting the brain tumor drugs market. Brain illnesses, which include several neurodegenerative, psychiatric, and developmental problems, are the reasons for death associated with brain damage worldwide. According to the American Medical Association (AMA), more than 20% of the world's population is expected to be 65 years or older by 2050.
Cancer, a global public health issue, ranks second in the cause of morbidity in the United States. The global elderly population and the emergence of novel diseases are expected to drive growth in the brain tumor medication market.
The brain tumor medication tackles abnormal cell growth in the brain and is administered in combination or alone, depending on their location, shape, and size. For example, Temozolomide, Avastin, and BiCNU carmustine are medications used to treat brain tumors. Government initiatives and increased knowledge about medical breakthroughs are expected to propel the industry growth in the coming years.
Don't pay for what you don't need
Customize your report by selecting specific countries or regions and save 30%!
The brain tumor drugs market was worth US$ 2.52 billion in 2022, at a 9% CAGR from 2017 to 2022.
Developments in medical treatment and advanced patient care for brain illnesses are available globally. Experiments and advancements in combination therapy with current and novel medications have resulted in people suffering from brain tumor problems.
The increased use of targeted therapeutics may restrain market growth. The pharmaceutical industry is focused on developing drugs that specifically target the eradication of cancer cells while causing no harm to normal bodily cells, as some cancer spread to the brain through different body parts. Bevacizumab, for example, prevents cancer cell replication, allowing cytotoxic chemotherapy medications that limit normal cell division to be used. Furthermore, the growing acceptability of these procedures and therapies is anticipated to create roadblocks in the use of traditional brain tumor medications, threatening market expansion.
| Historical CAGR (2017 to 2022) | 9% |
|---|---|
| Forecast CAGR (2023 to 2033) | 9.2% |
As per the FMI analysts, a valuation of US$ 6.30 billion by 2033 is estimated for the market.
| Year | Market Value |
|---|---|
| 2016 | US$ 1.43 billion |
| 2021 | US$ 2.23 billion |
| 2022 | US$ 2.52 billion |
| 2023 | US$ 2.65 billion |
| 2033 | US$ 6.30 billion |
Factors such as changing lifestyles and eating choices increased urbanization, and smoking habit is surging the cases of brain conditions among adults and elderly people. According to the WHO, nearly 23.0% of adults used tobacco in 2020. As a result, the increased incidence of smoking among adults contributes to the global increase in cancer cases.Furthermore, as the prevalence of various cancer kinds rises, so does the rate of diagnosis and treatment. For example, according to GLOBOCAN, roughly 19,300,000 persons worldwide were diagnosed with cancer in 2020.
Brain tumors account for around 1% to 2% of cancer death in the United States, with a significant fatality rate. The increased occurrence of brain tumors is due to factors such as strong radiation exposure that causes DNA to change and eventually lead to cancer.
Principal Consultant
The rising prevalence of brain cancer and rising diagnosis rates, particularly in industrialized nations, are creating a pool of patients in need of treatment. This, together with market participants' increased focus on research and development activities to introduce new medications with clinical benefits for the treatment and management of the illness, is propelling the brain tumor pharmaceuticals market forward.
Unmet needs, such as the availability of these medications on the market, associated with the various stages of brain cancer management, may aid in shifting research and development priorities and improving physicians' therapeutic approaches. As a result, many pharmaceutical companies are investing in research and development to find novel medications for the treatment of brain tumors.
Several side effects associated with brain tumor treatments, as well as the high costs of these drugs, are a few reasons restricting market expansion. Furthermore, lower brain tumor diagnosis and treatment rates, as well as limited reimbursement for these medications in underdeveloped countries, are projected to restrain market growth.
Brain cancer diagnosis and treatment rates are substantially lower in emerging countries than in developed countries. In China, for example, the prevalence of brain tumors was 14.82 per 100,000 individuals in 2021.
Get the data you need at a Fraction of the cost
Personalize your report by choosing insights you need
and save 40%!
Early detection and treatment of brain tumors are difficult due to variables such as the body's blood-brain barrier, which normally protects the spinal cord and brain from harmful substances. This barrier, however, also keeps many forms of chemotherapy out. Thus, improved methods for brain tumor diagnosis and treatment are required. The prevalence of brain tumors is steadily growing, which can be ascribed to advancements in detection and treatment procedures.
Prognostic indicators are vital in the creation of tailored medications and in increasing the survival rate of persons with brain tumors. Neurological and neuroimaging studies are utilized to diagnose glioma at an advanced stage. Assessment of genetic characteristics in biopsy specimens of brain tumor patients is one of the important tools for improved diagnosis and treatment of brain tumors. Furthermore, circulating nucleic acid in the blood and other biological fluids can be employed as a marker for the early detection and treatment of brain tumors.
Immunotherapy is a cancer treatment that aids the immune system in its battle against cancer. Immunotherapies are employed in a range of cancer treatments. Immunotherapy holds promise for treating brain cancer, which has traditionally been treated with chemotherapy, radiation therapy, and surgery. Immunotherapy, often known as biological treatment, uses living organisms to treat disease.
Vaccines are a promising new type of immunotherapy that boosts the immune system's ability to fight cancer. This market's growth is expected to be fueled by novel immunotherapy treatments for brain cancer. Furthermore, there are numerous authorized immunotherapies for various brain malignancies, and industry companies and universities are heavily working on researching and marketing new brain tumor immunotherapies.
As a result, this market may grow as universities increase their efforts to develop novel immunotherapy treatments. As a result, the aforementioned factors have contributed to the market's overall expansion.
The North American brain tumor market is expected to grow significantly during the forecast period. The United States is expected to lead the market because of its developed healthcare industry and increased awareness of sophisticated technologies among the populace in this area.
According to the American Brain Tumor Association, about 84,000 people were diagnosed with a primary brain tumor in 2021, and roughly 18,000 died as a result of a primary malignant brain tumor. Furthermore, more than 28,000 youngsters in the United States were diagnosed with a brain tumor in 2021, according to the same source.
The increased occurrence of brain tumors is likely to boost regional growth. Furthermore, the market analyzed in the United States is projected to be driven by regular product releases and pharmacological approvals, as well as considerable R&D initiatives for the treatment of brain tumors.
The surging clinical trials for brain tumor therapy in the United States are likely to boost the expansion of this market. As a result of the foregoing factors, the North American brain tumor drugs market is expected to expand significantly over the forecast period.
The market in Latin America is expanding due to an increase in brain tumor diagnosis and treatment, which has created a demand for these medications in the region. This, combined with the introduction of new pharmaceuticals in the region, is contributing to the region's market growth.
The frequency of primary brain tumors, favorable regulatory circumstances in leading European nations, and an increased emphasis on research activities for producing brain tumor drugs are driving the market in Europe.
According to national and regional estimates, around US$ 115.00 billion was spent on cancer care in Europe in 2019, with direct expenditures on cancer medications accounting for nearly US$ 35.00 to US$ 40.00 billion.
The market in the Asia Pacific is influenced by rising awareness of brain cancer, early detection, and increased clinical trial in drug delivery for brain cancer cells. Furthermore, increased knowledge regarding brain tumors and their forms in the region boosts the market growth.
According to brain tumor research, the average rating of brain tumor care in Australia was the lowest of all cancers, with a score of 8.37 out of 10. Moreover, in 2018, nearly two thousand people died due to brain cancer in the Asia Pacific.
Prominent Participants in the Market
| Attribute | Details |
|---|---|
| Market Size Value in 2023 | US$ 2.65 billion |
| Market Size Value in 2033 | US$ 6.30 billion |
| Market Analysis | US$ billion for Value |
| Key Region Covered | North America; Latin America; Europe; Asia Pacific; The Middle East and Africa |
| Key Segments | By Therapy, By Indication, By Distribution Channel, By Region |
| Key Companies Profiled | AstraZeneca plc; Johnson & Johnson Inc; Merck & Co; Pfizer Inc; F. Hoffmann-La Roche Ltd; Y-mAbs Therapeutics, Inc; Shimadzu Corporation; Bristol-Myers Squibb; Bayer AG; Dr. Reddy's Laboratories Ltd; Among others |
| Report Coverage | Market Forecast, Company Share Analysis, Competition Intelligence, DROT Analysis, Market Dynamics and Challenges, and Strategic Growth Initiatives |
| Customization & Pricing | Available upon Request |
Surging neurological condition is the key driver of the market.
The increased use of targeted therapeutics may restrain the market growth.
The market is likely to experience a 9.2% CAGR until 2033.
The market is predicted to be worth US$ 6.30 billion in 2033.
North America is likely to dominate the market.
1. Executive Summary | Brain Tumor Drugs Market 1.1. Global Market Outlook 1.2. Demand-side Trends 1.3. Supply-side Trends 1.4. Technology Roadmap Analysis 1.5. Analysis and Recommendations 2. Market Overview 2.1. Market Coverage / Taxonomy 2.2. Market Definition / Scope / Limitations 3. Market Background 3.1. Market Dynamics 3.1.1. Drivers 3.1.2. Restraints 3.1.3. Opportunity 3.1.4. Trends 3.2. Scenario Forecast 3.2.1. Demand in Optimistic Scenario 3.2.2. Demand in Likely Scenario 3.2.3. Demand in Conservative Scenario 3.3. Opportunity Map Analysis 3.4. Investment Feasibility Matrix 3.5. PESTLE and Porter’s Analysis 3.6. Regulatory Landscape 3.6.1. By Key Regions 3.6.2. By Key Countries 3.7. Regional Parent Market Outlook 4. Global Market Analysis 2018 to 2022 and Forecast, 2023 to 2033 4.1. Historical Market Size Value (US$ Million) Analysis, 2018 to 2022 4.2. Current and Future Market Size Value (US$ Million) Projections, 2023 to 2033 4.2.1. Y-o-Y Growth Trend Analysis 4.2.2. Absolute $ Opportunity Analysis 5. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Drug Class 5.1. Introduction / Key Findings 5.2. Historical Market Size Value (US$ Million) Analysis By Drug Class, 2018 to 2022 5.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By Drug Class, 2023 to 2033 5.3.1. Temozolomide 5.3.2. Carmustine 5.3.3. Cisplatin 5.3.4. Bevacizumab 5.3.5. Geftinib 5.3.6. Erlotinib 5.4. Y-o-Y Growth Trend Analysis By Drug Class, 2018 to 2022 5.5. Absolute $ Opportunity Analysis By Drug Class, 2023 to 2033 6. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Therapy 6.1. Introduction / Key Findings 6.2. Historical Market Size Value (US$ Million) Analysis By Therapy, 2018 to 2022 6.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By Therapy, 2023 to 2033 6.3.1. Targeted Therapy 6.3.2. Chemotherapy 6.3.3. Immunotherapy 6.4. Y-o-Y Growth Trend Analysis By Therapy, 2018 to 2022 6.5. Absolute $ Opportunity Analysis By Therapy, 2023 to 2033 7. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Indication 7.1. Introduction / Key Findings 7.2. Historical Market Size Value (US$ Million) Analysis By Indication , 2018 to 2022 7.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By Indication , 2023 to 2033 7.3.1. Pituitary Tumor 7.3.2. Meningioma 7.3.3. Glioblastoma 7.4. Y-o-Y Growth Trend Analysis By Indication , 2018 to 2022 7.5. Absolute $ Opportunity Analysis By Indication , 2023 to 2033 8. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Distribution Channel 8.1. Introduction / Key Findings 8.2. Historical Market Size Value (US$ Million) Analysis By Distribution Channel, 2018 to 2022 8.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By Distribution Channel, 2023 to 2033 8.3.1. Hospital Pharmacies 8.3.2. Retail Pharmacies 8.3.3. Online Pharmacies 8.4. Y-o-Y Growth Trend Analysis By Distribution Channel, 2018 to 2022 8.5. Absolute $ Opportunity Analysis By Distribution Channel, 2023 to 2033 9. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Region 9.1. Introduction 9.2. Historical Market Size Value (US$ Million) Analysis By Region, 2018 to 2022 9.3. Current Market Size Value (US$ Million) Analysis and Forecast By Region, 2023 to 2033 9.3.1. North America 9.3.2. Latin America 9.3.3. Europe 9.3.4. South Asia 9.3.5. East Asia 9.3.6. Oceania 9.3.7. MEA 9.4. Market Attractiveness Analysis By Region 10. North America Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country 10.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022 10.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033 10.2.1. By Country 10.2.1.1. USA 10.2.1.2. Canada 10.2.2. By Drug Class 10.2.3. By Therapy 10.2.4. By Indication 10.2.5. By Distribution Channel 10.3. Market Attractiveness Analysis 10.3.1. By Country 10.3.2. By Drug Class 10.3.3. By Therapy 10.3.4. By Indication 10.3.5. By Distribution Channel 10.4. Key Takeaways 11. Latin America Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country 11.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022 11.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033 11.2.1. By Country 11.2.1.1. Brazil 11.2.1.2. Mexico 11.2.1.3. Rest of Latin America 11.2.2. By Drug Class 11.2.3. By Therapy 11.2.4. By Indication 11.2.5. By Distribution Channel 11.3. Market Attractiveness Analysis 11.3.1. By Country 11.3.2. By Drug Class 11.3.3. By Therapy 11.3.4. By Indication 11.3.5. By Distribution Channel 11.4. Key Takeaways 12. Europe Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country 12.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022 12.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033 12.2.1. By Country 12.2.1.1. Germany 12.2.1.2. United kingdom 12.2.1.3. France 12.2.1.4. Spain 12.2.1.5. Italy 12.2.1.6. Rest of Europe 12.2.2. By Drug Class 12.2.3. By Therapy 12.2.4. By Indication 12.2.5. By Distribution Channel 12.3. Market Attractiveness Analysis 12.3.1. By Country 12.3.2. By Drug Class 12.3.3. By Therapy 12.3.4. By Indication 12.3.5. By Distribution Channel 12.4. Key Takeaways 13. South Asia Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country 13.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022 13.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033 13.2.1. By Country 13.2.1.1. India 13.2.1.2. Malaysia 13.2.1.3. Singapore 13.2.1.4. Thailand 13.2.1.5. Rest of South Asia 13.2.2. By Drug Class 13.2.3. By Therapy 13.2.4. By Indication 13.2.5. By Distribution Channel 13.3. Market Attractiveness Analysis 13.3.1. By Country 13.3.2. By Drug Class 13.3.3. By Therapy 13.3.4. By Indication 13.3.5. By Distribution Channel 13.4. Key Takeaways 14. East Asia Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country 14.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022 14.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033 14.2.1. By Country 14.2.1.1. China 14.2.1.2. Japan 14.2.1.3. South Korea 14.2.2. By Drug Class 14.2.3. By Therapy 14.2.4. By Indication 14.2.5. By Distribution Channel 14.3. Market Attractiveness Analysis 14.3.1. By Country 14.3.2. By Drug Class 14.3.3. By Therapy 14.3.4. By Indication 14.3.5. By Distribution Channel 14.4. Key Takeaways 15. Oceania Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country 15.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022 15.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033 15.2.1. By Country 15.2.1.1. Australia 15.2.1.2. New Zealand 15.2.2. By Drug Class 15.2.3. By Therapy 15.2.4. By Indication 15.2.5. By Distribution Channel 15.3. Market Attractiveness Analysis 15.3.1. By Country 15.3.2. By Drug Class 15.3.3. By Therapy 15.3.4. By Indication 15.3.5. By Distribution Channel 15.4. Key Takeaways 16. MEA Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country 16.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022 16.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033 16.2.1. By Country 16.2.1.1. GCC Countries 16.2.1.2. South Africa 16.2.1.3. Israel 16.2.1.4. Rest of MEA 16.2.2. By Drug Class 16.2.3. By Therapy 16.2.4. By Indication 16.2.5. By Distribution Channel 16.3. Market Attractiveness Analysis 16.3.1. By Country 16.3.2. By Drug Class 16.3.3. By Therapy 16.3.4. By Indication 16.3.5. By Distribution Channel 16.4. Key Takeaways 17. Key Countries Market Analysis 17.1. USA 17.1.1. Pricing Analysis 17.1.2. Market Share Analysis, 2022 17.1.2.1. By Drug Class 17.1.2.2. By Therapy 17.1.2.3. By Indication 17.1.2.4. By Distribution Channel 17.2. Canada 17.2.1. Pricing Analysis 17.2.2. Market Share Analysis, 2022 17.2.2.1. By Drug Class 17.2.2.2. By Therapy 17.2.2.3. By Indication 17.2.2.4. By Distribution Channel 17.3. Brazil 17.3.1. Pricing Analysis 17.3.2. Market Share Analysis, 2022 17.3.2.1. By Drug Class 17.3.2.2. By Therapy 17.3.2.3. By Indication 17.3.2.4. By Distribution Channel 17.4. Mexico 17.4.1. Pricing Analysis 17.4.2. Market Share Analysis, 2022 17.4.2.1. By Drug Class 17.4.2.2. By Therapy 17.4.2.3. By Indication 17.4.2.4. By Distribution Channel 17.5. Germany 17.5.1. Pricing Analysis 17.5.2. Market Share Analysis, 2022 17.5.2.1. By Drug Class 17.5.2.2. By Therapy 17.5.2.3. By Indication 17.5.2.4. By Distribution Channel 17.6. United kingdom 17.6.1. Pricing Analysis 17.6.2. Market Share Analysis, 2022 17.6.2.1. By Drug Class 17.6.2.2. By Therapy 17.6.2.3. By Indication 17.6.2.4. By Distribution Channel 17.7. France 17.7.1. Pricing Analysis 17.7.2. Market Share Analysis, 2022 17.7.2.1. By Drug Class 17.7.2.2. By Therapy 17.7.2.3. By Indication 17.7.2.4. By Distribution Channel 17.8. Spain 17.8.1. Pricing Analysis 17.8.2. Market Share Analysis, 2022 17.8.2.1. By Drug Class 17.8.2.2. By Therapy 17.8.2.3. By Indication 17.8.2.4. By Distribution Channel 17.9. Italy 17.9.1. Pricing Analysis 17.9.2. Market Share Analysis, 2022 17.9.2.1. By Drug Class 17.9.2.2. By Therapy 17.9.2.3. By Indication 17.9.2.4. By Distribution Channel 17.10. India 17.10.1. Pricing Analysis 17.10.2. Market Share Analysis, 2022 17.10.2.1. By Drug Class 17.10.2.2. By Therapy 17.10.2.3. By Indication 17.10.2.4. By Distribution Channel 17.11. Malaysia 17.11.1. Pricing Analysis 17.11.2. Market Share Analysis, 2022 17.11.2.1. By Drug Class 17.11.2.2. By Therapy 17.11.2.3. By Indication 17.11.2.4. By Distribution Channel 17.12. Singapore 17.12.1. Pricing Analysis 17.12.2. Market Share Analysis, 2022 17.12.2.1. By Drug Class 17.12.2.2. By Therapy 17.12.2.3. By Indication 17.12.2.4. By Distribution Channel 17.13. Thailand 17.13.1. Pricing Analysis 17.13.2. Market Share Analysis, 2022 17.13.2.1. By Drug Class 17.13.2.2. By Therapy 17.13.2.3. By Indication 17.13.2.4. By Distribution Channel 17.14. China 17.14.1. Pricing Analysis 17.14.2. Market Share Analysis, 2022 17.14.2.1. By Drug Class 17.14.2.2. By Therapy 17.14.2.3. By Indication 17.14.2.4. By Distribution Channel 17.15. Japan 17.15.1. Pricing Analysis 17.15.2. Market Share Analysis, 2022 17.15.2.1. By Drug Class 17.15.2.2. By Therapy 17.15.2.3. By Indication 17.15.2.4. By Distribution Channel 17.16. South Korea 17.16.1. Pricing Analysis 17.16.2. Market Share Analysis, 2022 17.16.2.1. By Drug Class 17.16.2.2. By Therapy 17.16.2.3. By Indication 17.16.2.4. By Distribution Channel 17.17. Australia 17.17.1. Pricing Analysis 17.17.2. Market Share Analysis, 2022 17.17.2.1. By Drug Class 17.17.2.2. By Therapy 17.17.2.3. By Indication 17.17.2.4. By Distribution Channel 17.18. New Zealand 17.18.1. Pricing Analysis 17.18.2. Market Share Analysis, 2022 17.18.2.1. By Drug Class 17.18.2.2. By Therapy 17.18.2.3. By Indication 17.18.2.4. By Distribution Channel 17.19. GCC Countries 17.19.1. Pricing Analysis 17.19.2. Market Share Analysis, 2022 17.19.2.1. By Drug Class 17.19.2.2. By Therapy 17.19.2.3. By Indication 17.19.2.4. By Distribution Channel 17.20. South Africa 17.20.1. Pricing Analysis 17.20.2. Market Share Analysis, 2022 17.20.2.1. By Drug Class 17.20.2.2. By Therapy 17.20.2.3. By Indication 17.20.2.4. By Distribution Channel 17.21. Israel 17.21.1. Pricing Analysis 17.21.2. Market Share Analysis, 2022 17.21.2.1. By Drug Class 17.21.2.2. By Therapy 17.21.2.3. By Indication 17.21.2.4. By Distribution Channel 18. Market Structure Analysis 18.1. Competition Dashboard 18.2. Competition Benchmarking 18.3. Market Share Analysis of Top Players 18.3.1. By Regional 18.3.2. By Drug Class 18.3.3. By Therapy 18.3.4. By Indication 18.3.5. By Distribution Channel 19. Competition Analysis 19.1. Competition Deep Dive 19.1.1. Genetech USAA 19.1.1.1. Overview 19.1.1.2. Product Portfolio 19.1.1.3. Profitability by Market Segments 19.1.1.4. Sales Footprint 19.1.1.5. Strategy Overview 19.1.1.5.1. Marketing Strategy 19.1.2. Bristol Myers Squibb 19.1.2.1. Overview 19.1.2.2. Product Portfolio 19.1.2.3. Profitability by Market Segments 19.1.2.4. Sales Footprint 19.1.2.5. Strategy Overview 19.1.2.5.1. Marketing Strategy 19.1.3. Hoffmann- La Roche 19.1.3.1. Overview 19.1.3.2. Product Portfolio 19.1.3.3. Profitability by Market Segments 19.1.3.4. Sales Footprint 19.1.3.5. Strategy Overview 19.1.3.5.1. Marketing Strategy 19.1.4. AstraZeneca Plc. 19.1.4.1. Overview 19.1.4.2. Product Portfolio 19.1.4.3. Profitability by Market Segments 19.1.4.4. Sales Footprint 19.1.4.5. Strategy Overview 19.1.4.5.1. Marketing Strategy 19.1.5. Pfizer Inc. 19.1.5.1. Overview 19.1.5.2. Product Portfolio 19.1.5.3. Profitability by Market Segments 19.1.5.4. Sales Footprint 19.1.5.5. Strategy Overview 19.1.5.5.1. Marketing Strategy 19.1.6. Novartis AG 19.1.6.1. Overview 19.1.6.2. Product Portfolio 19.1.6.3. Profitability by Market Segments 19.1.6.4. Sales Footprint 19.1.6.5. Strategy Overview 19.1.6.5.1. Marketing Strategy 19.1.7. Antisense Pharma 19.1.7.1. Overview 19.1.7.2. Product Portfolio 19.1.7.3. Profitability by Market Segments 19.1.7.4. Sales Footprint 19.1.7.5. Strategy Overview 19.1.7.5.1. Marketing Strategy 19.1.8. Merck & Co 19.1.8.1. Overview 19.1.8.2. Product Portfolio 19.1.8.3. Profitability by Market Segments 19.1.8.4. Sales Footprint 19.1.8.5. Strategy Overview 19.1.8.5.1. Marketing Strategy 19.1.9. MacLeod’s Pharmaceutical Limited 19.1.9.1. Overview 19.1.9.2. Product Portfolio 19.1.9.3. Profitability by Market Segments 19.1.9.4. Sales Footprint 19.1.9.5. Strategy Overview 19.1.9.5.1. Marketing Strategy 19.1.10. Mankind Pharma 19.1.10.1. Overview 19.1.10.2. Product Portfolio 19.1.10.3. Profitability by Market Segments 19.1.10.4. Sales Footprint 19.1.10.5. Strategy Overview 19.1.10.5.1. Marketing Strategy 19.1.11. Siemens Healthineers AG 19.1.11.1. Overview 19.1.11.2. Product Portfolio 19.1.11.3. Profitability by Market Segments 19.1.11.4. Sales Footprint 19.1.11.5. Strategy Overview 19.1.11.5.1. Marketing Strategy 19.1.12. Dr. Reddy’s Laboratories Ltd. 19.1.12.1. Overview 19.1.12.2. Product Portfolio 19.1.12.3. Profitability by Market Segments 19.1.12.4. Sales Footprint 19.1.12.5. Strategy Overview 19.1.12.5.1. Marketing Strategy 20. Assumptions & Acronyms Used 21. Research Methodology
Explore Healthcare Insights
View Reports
Brain Tumor Drugs Market
